GlassScriptPhysician profile
Adam J Bard
NPI 1477531218
$2,726.73
in general payments reported to CMS, 2019-2025
19 companies · $948 in 2025
The $948 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $487 · 2021: $139 · 2022: $281 · 2023: $287 · 2024: $466 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.96 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $642.45 | 2020-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $171.45 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $170.93 | 2019-2025 | |
| Amgen INC. | $151.98 | 2023-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $146.69 | 2024-2025 | Fanapt |
| Glaxosmithkline, LLC. | $125.21 | 2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $108.91 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.47 | 2019-2025 | Xifaxan |
| Actelion Pharmaceuticals US, INC. | $78.85 | 2025 | Opsumit, Opsynvi, Uptravi |
| Exact Sciences Corporation | $64.37 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $54.47 | 2020 | |
| Arbor Pharmaceuticals, INC. | $50.45 | 2019-2020 | |
| Lilly USA, LLC | $47.81 | 2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $44.68 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.60 | 2025 | |
| Medtronic Minimed, INC. | $21.20 | 2020 | |
| Currax Pharmaceuticals LLC | $15.20 | 2025 | Contrave |
| Janssen Pharmaceuticals, INC | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.